Filgrastim Dosing Recommendations

Standard Dose for Chemotherapy-Induced Neutropenia

The National Comprehensive Cancer Network recommends a standard dose of filgrastim of 5 mcg/kg/day administered subcutaneously, starting 24-72 hours after completion of chemotherapy and continuing until post-nadir absolute neutrophil count (ANC) recovery to normal or near-normal levels 1, 2, 3
The American Society of Clinical Oncology suggests that the standard dose of 5 mcg/kg/day is appropriate for all clinical settings except peripheral blood progenitor cell (PBPC) mobilization, with subcutaneous administration being strongly preferred over intravenous due to superior pharmacokinetic profiles 2, 4

For peripheral blood progenitor cell mobilization, the American Society of Clinical Oncology recommends a higher dose of 10 mcg/kg/day, which results in improved leukapheresis products compared to standard dosing 2, 4, 5, 6
The National Comprehensive Cancer Network suggests that alternative scheduling (5 mcg/kg twice daily vs. 10 mcg/kg single injection) may also improve mobilization 2, 4

For patients undergoing bone marrow transplantation, the American Society of Clinical Oncology recommends starting filgrastim at 10 mcg/kg/day and tapering to 5 mcg/kg/day once ANC recovers to ≥1,000/μL for at least 3 days, and discontinuing once ANC remains >1,000/μL for 3 additional days 2, 4

The National Comprehensive Cancer Network recommends rounding the dose to the nearest vial size as an appropriate cost-saving strategy without clinical detriment, according to institution-defined weight limits 1, 2, 3, 4, 5, 6
The American Society of Clinical Oncology suggests rotating injection sites when administering multiple doses over several days to prevent local tissue irritation, although this citation is from Praxis Medical Insights, an alternative source is not provided 7

The National Comprehensive Cancer Network advises against using pegfilgrastim dosing interchangeably with filgrastim, as pegfilgrastim requires a single 6 mg dose per cycle, not daily dosing 1, 3, 8
The American Society of Clinical Oncology recommends avoiding same-day administration with chemotherapy for both filgrastim and pegfilgrastim 3

These recommendations are based on guidelines from the American Society of Clinical Oncology and the National Comprehensive Cancer Network with Category 1 evidence, representing the highest level of consensus from multiple randomized controlled trials 1, 2, 3, 4, 5, 6

The American Society of Clinical Oncology (ASCO) recommends that subcutaneous injection is the preferred route for filgrastim in all clinical settings. 9
The National Comprehensive Cancer Network (NCCN) reinforces that subcutaneous injection is the preferred route for all three G‑CSF agents—filgrastim, pegfilgrastim, and sargramostim. 10

ASCO’s 2000 guideline states that G‑CSF “can be administered subcutaneously or intravenously as clinically indicated,” allowing intravenous use in specific clinical circumstances (e.g., lack of subcutaneous access). 9

The standard dose for chemotherapy‑induced neutropenia is 5 µg/kg per day, applicable to both subcutaneous and intravenous administration. 9
For peripheral blood progenitor cell mobilization, the dose is increased to 10 µg/kg per day, regardless of the administration route. 9

G‑CSF should be started 24–72 hours after completion of chemotherapy and must not be given on the same day as chemotherapy. 11

Do not use intravenous administration solely for convenience when subcutaneous access is available; subcutaneous delivery is superior for neutrophil recovery. 10
G‑CSF must not be administered within 24 hours of chemotherapy, as early dosing raises the risk of thrombocytopenia. 11